Industry Veterans Launch Maprium – an innovative technology to drive efficiencies and compliance in global Managed Access Programmes (MAPS).

Founded by ex-Clinigen and IDIS executive, Romina Oxborough, PhD, Maprium has developed an innovative technology that enables biopharmaceutical companies to more efficiently manage global Managed Access Programmes in one single solution.

Currently biopharmaceutical companies use fragmented tools, spreadsheets and a variety of vendor-owned systems – creating inefficiencies and introducing risk. Maprium enables them to manage access programmes in a timely, accurate, and intelligent way - ensuring equitable patient access, full compliance and real-world insights while reducing the operational and regulatory burden on pharmaceutical and biotech teams.

Maprium’s solution can be used to manage multiple programmes across different use-cases (compassionate use, named patient, post-trial access) from one single solution - bringing together governance, operational delivery, and real-time visibility in a way that reflects both regulatory reality and day-to-day execution.

Maprium’s platform has been designed and built by a highly experienced team including MAP and clinical trials technology experts, with real-world experience of the challenges biopharma companies face. The team have decades of expertise and have collectively delivered thousands of global access programmes and clinical trials across multiple therapeutic categories, including oncology and rare disease.

Says Founder, Romina Oxborough “Maprium is built on a strong foundation of quality, compliance, and operational excellence, informed by deep, hands-on experience across access programmes and technology-enabled solutions. I’m very much looking forward to working with organisations across the life sciences ecosystem who share the goal of improving patient access, responsibly and at scale.”

Across the life sciences sector, globally, challenges remain persistently clear: patients with unmet medical needs still face inequitable and delayed access to medicines — not because of science or intent, but because market access pathways are operationally complex, fragmented, or under-supported. Maprium is designed to streamline processes whilst managing complex and rigorous regulatory and market access challenges, with the ability to manage multiple vendors across the supply chain and providing a single source of real world and compliance data.  

The company is backed by a strong team of experienced industry veterans and venture capital funds who were impressed by Romina’s vision and who share an appreciation of unmet market needs and demands.

Says Investor Director, and early access pioneer, Natalie Douglas:

“In a mature MAP market, now is the right time for innovation. We need to meet the advancing needs of the biopharma industry and solve continued patient access challenges. Maprium’s integrated, vendor agnostic platform is a unique solution providing choice and an independent point of view, to simplify the management and co-ordination of complex global patient programs.”

Niall McKeon, CFO at Abbey International Finance says: “There is a clear market need for the Maprium offer. Given the expertise and experience of the Maprium team, we have every faith that this technology will transform how MAPs are managed – creating efficiencies for BioPharma and importantly, improving fair and equitable access for patients globally.”